Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease

FAME 2

Clinicaltrials.gov NCT01132495

Bernard De Bruyne, Nico H.J. Pijls, William F Fearon, Peter Juni, Emanuele Barbato, Pim Tonino, for the FAME 2 study group

Potential conflicts of interest

Speaker's name: Bernard De Bruyne
☐ I have the following potential conflicts of interest to report:
Research contracts Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s)

☐ I do not have any potential conflict of interest

Study Supported by St. Jude Medical


Background

- In patients with stable coronary disease, PCI has not been shown to improve prognosis
- FAME 1 demonstrated the superiority of FFR-guided over angiography-guided PCI
- In previous trials, revascularization has been guided by the angiographic appearance of the lesions
- It is likely that in previous trials a sizable proportion of patients had no or little ischemia


Objective

To compare clinical outcomes of FFRguided contemporary PCI plus the best available medical therapy (MT) versus MT alone in patients with stable coronary disease


Flow Chart




Primary Outcomes



Urgent Revascularization



Kaplan-Meier plots of Landmark Analysis of Death or MI



Conclusions

- In patients with stable coronary artery disease, FFR-guided PCI, improves patient outcome as compared with medical therapy alone
- This improvement is driven by a dramatic decrease in the need for urgent revascularization for ACS
- In patients with functionally non-significant stenoses medical therapy alone resulted in an excellent outcome, regardless of the angiographic appearance of the stenoses